Matches in Wikidata for { <http://www.wikidata.org/entity/Q61955586> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- Q61955586 description "clinical trial" @default.
- Q61955586 description "ensayo clínico" @default.
- Q61955586 description "ensayu clínicu" @default.
- Q61955586 description "klinisch onderzoek" @default.
- Q61955586 description "клінічне випробування" @default.
- Q61955586 description "临床试验" @default.
- Q61955586 name "Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma" @default.
- Q61955586 type Item @default.
- Q61955586 label "Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma" @default.
- Q61955586 prefLabel "Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma" @default.
- Q61955586 P1050 Q61955586-1AEC9ABB-4CA6-42EF-B013-D871012D6736 @default.
- Q61955586 P1132 Q61955586-A6DFCB59-4897-43F3-9864-C450D121658F @default.
- Q61955586 P1476 Q61955586-DFC31CFC-7964-4FEA-9E2E-2E924C05AC31 @default.
- Q61955586 P17 Q61955586-165A15DF-B29A-4AF8-892A-66A7DFD1A8FC @default.
- Q61955586 P17 Q61955586-1746C37F-0CC1-41C6-95DF-4BA9B1A09E38 @default.
- Q61955586 P17 Q61955586-ADEFACC2-4D36-43BE-BAF5-E4A586A511EF @default.
- Q61955586 P17 Q61955586-ED74F48D-0013-43FC-91BE-28A3B6DC9C1C @default.
- Q61955586 P2899 Q61955586-D9EF168C-6AD0-44DC-B080-9CB37AFDDA57 @default.
- Q61955586 P3098 Q61955586-AFB15DBB-A25A-460C-8FFC-33A16B1161A8 @default.
- Q61955586 P31 Q61955586-549D8A5D-88F8-426F-8334-36E7AA47DB4F @default.
- Q61955586 P580 Q61955586-45DEDA3A-F4B6-4B27-AECD-2CCA4FD0B491 @default.
- Q61955586 P582 Q61955586-89F4947E-A622-493E-8A3C-5BAAF816F5D6 @default.
- Q61955586 P6099 Q61955586-C482DAAE-B58E-4049-95BB-CBD512F3F055 @default.
- Q61955586 P6153 Q61955586-0108BCA5-F7B4-4678-9A4C-62A9041FD252 @default.
- Q61955586 P6153 Q61955586-44B4A2A2-4BFA-49C9-9B14-93FAF0A704A9 @default.
- Q61955586 P6153 Q61955586-5177BF45-7405-4949-93C7-8575A5AD0D4D @default.
- Q61955586 P6153 Q61955586-650810F4-A4A0-4093-95B1-36E858EA7EA6 @default.
- Q61955586 P6153 Q61955586-7B053F30-1BCC-408D-B11B-91898E14F761 @default.
- Q61955586 P6153 Q61955586-E2167E1F-178E-4E0B-8C84-3AB93D3CEBF4 @default.
- Q61955586 P8005 Q61955586-A5BB068E-B2DF-4274-8830-FDC31B1B417F @default.
- Q61955586 P8363 Q61955586-FB54EE35-ECFC-4239-9477-F7F0EA68195C @default.
- Q61955586 P859 Q61955586-06DAC66C-5158-4980-BAFB-BB029E67AF46 @default.
- Q61955586 P1050 Q208414 @default.
- Q61955586 P1132 "+124" @default.
- Q61955586 P1476 "A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)" @default.
- Q61955586 P17 Q142 @default.
- Q61955586 P17 Q183 @default.
- Q61955586 P17 Q29 @default.
- Q61955586 P17 Q30 @default.
- Q61955586 P2899 "+18" @default.
- Q61955586 P3098 "NCT01471210" @default.
- Q61955586 P31 Q30612 @default.
- Q61955586 P580 "2012-02-01T00:00:00Z" @default.
- Q61955586 P582 "2016-04-01T00:00:00Z" @default.
- Q61955586 P6099 Q5452194 @default.
- Q61955586 P6153 Q1159198 @default.
- Q61955586 P6153 Q131252 @default.
- Q61955586 P6153 Q1808012 @default.
- Q61955586 P6153 Q213439 @default.
- Q61955586 P6153 Q5637237 @default.
- Q61955586 P6153 Q739627 @default.
- Q61955586 P8005 Q76651189 @default.
- Q61955586 P8363 Q78089383 @default.
- Q61955586 P859 Q266423 @default.